DECLARE Dapagliflozin Effect on CardiovascuLAR Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2013
This article has no abstract
Epistemonikos ID: 56a1d2f4eb73239a7107bd67ec2ed08ab8d235a4
First added on: Apr 16, 2025